H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Tempest Therapeutics (TPST) to $16 from $47 and keeps a Buy rating on the shares following the Q4 report. The firm sees ongoing financing risk of the company to move amezalpat into a pivotal study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TPST: